Spots Global Cancer Trial Database for car t cell
Every month we try and update this database with for car t cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | NCT04503980 | Colorectal Canc... Ovarian Cancer | αPD1-MSLN-CAR T... | 18 Years - 70 Years | Shanghai Cell Therapy Group Co.,Ltd | |
| Study of bb2121 in Multiple Myeloma | NCT02658929 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies | NCT05705570 | Acute Lymphobla... Acute Lymphobla... B-cell Lymphoma... B-cell Lymphoma... Chronic Lymphoc... Chronic Lymphoc... | Cyclophosphamid... Fludarabine Chimeric antige... | 2 Years - 70 Years | Hospital Israelita Albert Einstein | |
| Study of bb2121 in Multiple Myeloma | NCT02658929 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL | NCT03373071 | CD19-ALL CD19-LNH | CD19-CAR T cell | 6 Months - 25 Years | Bambino Gesù Hospital and Research Institute | |
| A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies | NCT05705570 | Acute Lymphobla... Acute Lymphobla... B-cell Lymphoma... B-cell Lymphoma... Chronic Lymphoc... Chronic Lymphoc... | Cyclophosphamid... Fludarabine Chimeric antige... | 2 Years - 70 Years | Hospital Israelita Albert Einstein | |
| Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma | NCT03361748 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | NCT03573700 | Acute Lymphobla... Acute Lymphobla... | Cyclophosphamid... Fludarabine Mesna CliniMACS CD19- specific ... | - 21 Years | St. Jude Children's Research Hospital | |
| Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | NCT05768880 | Diffuse Intrins... Diffuse Midline... Recurrent CNS T... Recurrent, CNS ... Refractory Prim... | SC-CAR4BRAIN | 1 Year - 26 Years | Seattle Children's Hospital | |
| αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | NCT04503980 | Colorectal Canc... Ovarian Cancer | αPD1-MSLN-CAR T... | 18 Years - 70 Years | Shanghai Cell Therapy Group Co.,Ltd | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM | NCT03283631 | Recurrent Gliob... Recurrent Glios... | EGFRvIII-CARs | 18 Years - | Duke University | |
| CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) | NCT06002659 | B-cell Lymphoma | CAR20(NAP)-T Cyclophosphamid... Fludarabine | - | Uppsala University | |
| A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer | NCT05911217 | Pancreatic Canc... | CT041 autologou... | 18 Years - 79 Years | CARsgen Therapeutics Co., Ltd. | |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | NCT03744676 | Lymphoma, Non-H... Lymphoma Lymphoma, B-Cel... Lymphoma, Large... Neoplasms Neoplasms by Hi... Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... | lisocabtagene m... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma | NCT05054257 | Relapsed or Ref... Non-Hodgkin's L... Non-Hodgkin's L... | Autologous CAR1... | 18 Years - 80 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | NCT03448978 | Multiple Myelom... | Descartes-08 Fludarabine Cyclophosphamid... | 18 Years - | Cartesian Therapeutics | |
| Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | NCT02311621 | Neuroblastoma Ganglioneurobla... | Patient Derived... Patient Derived... Patient Derived... | 18 Months - 26 Years | Seattle Children's Hospital | |
| Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) | NCT05353530 | Glioblastoma Mu... Glioblastoma | Ex-Vivo expande... | 18 Years - 80 Years | University of Florida | |
| Descartes-11 in Multiple Myeloma | NCT03994705 | Multiple Myelom... | Descartes-11 Fludarabine Cyclophosphamid... | 18 Years - | Cartesian Therapeutics | |
| Study of bb2121 in Multiple Myeloma | NCT02658929 | Multiple Myelom... | bb2121 | 18 Years - | Celgene | |
| Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | NCT05768880 | Diffuse Intrins... Diffuse Midline... Recurrent CNS T... Recurrent, CNS ... Refractory Prim... | SC-CAR4BRAIN | 1 Year - 26 Years | Seattle Children's Hospital | |
| A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma | NCT03244306 | Leukemia | Patient-derived... | 1 Year - 26 Years | Seattle Children's Hospital | |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT03618381 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma | second generati... second generati... | 1 Year - 30 Years | Seattle Children's Hospital | |
| A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma | NCT03244306 | Leukemia | Patient-derived... | 1 Year - 26 Years | Seattle Children's Hospital | |
| Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | NCT04581473 | Gastric Adenoca... Pancreatic Canc... Gastroesophagea... | CT041 autologou... Physician's Cho... | 18 Years - 75 Years | CARsgen Therapeutics Co., Ltd. | |
| Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG | NCT06221553 | DIPG Brain Tumo... Diffuse Intrins... | B7H3 specific C... | 1 Year - 18 Years | Chulalongkorn University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
